|
|
|
Pharmathen’s aim is to become the leading generic development company within the E.U.. We shall accomplish this target with:
| |
With the development of 10 new generic molecules every year |
| |
Dossiers fully compliant to E.U. standards, available at least 4 years ahead of patent expiry in the major E.U. generic markets |
| |
Develop new business in the U.S. and Japan |
| |
Introduction of new and innovative health care products in the local market |
|
|
|